Abstract
In a randomized pilot study we compared the antiplatelet effects of aspirin and BM 13.177 in two groups of 7 patients each undergoing PTCA. As compared with the pretreatment values template bleeding time was prolonged and collagen induced aggregation was inhibited in PRP and WB in all patients. In the course of angiography and PTCA a rise in platelet factor 4 and beta thromboglobulin was observed in both groups, followed by a decrease below the baseline levels. Thromboxane B2 in plasma and serum decreased in the aspirin group but remained unchanged during BM 13.177 treatment. In PRP and WB aggregation induced by U 46 619 was inhibited after ingestion of BM 13.177 but not following ASA. After three months a control coronary angiography was done. There was no difference in regard to the degree of restenosis between both groups. Medication was well tolerated, compliance was good and no side effects were noted.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
-
Angioplasty, Balloon*
-
Arteriosclerosis / therapy*
-
Aspirin / therapeutic use*
-
Bleeding Time
-
Blood Platelets / drug effects*
-
Clinical Trials as Topic
-
Collagen / pharmacology
-
Cyclooxygenase Inhibitors*
-
Female
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Platelet Aggregation / drug effects
-
Prostaglandin Endoperoxides, Synthetic / pharmacology
-
Receptors, Cell Surface / drug effects*
-
Receptors, Prostaglandin / drug effects*
-
Receptors, Thromboxane
-
Sulfonamides / therapeutic use*
-
Thromboxane B2 / blood
-
Thromboxanes / blood
Substances
-
Cyclooxygenase Inhibitors
-
Fibrinolytic Agents
-
Prostaglandin Endoperoxides, Synthetic
-
Receptors, Cell Surface
-
Receptors, Prostaglandin
-
Receptors, Thromboxane
-
Sulfonamides
-
Thromboxanes
-
Thromboxane B2
-
sulotroban
-
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
-
Collagen
-
Aspirin